Weekly prescription tracker

Our weekly prescription tracker assesses US prescription data and US monthly sales reported for key drugs and therapeutic categories by Symphony Health/Bloomberg.

Weekly prescription tracker

Our weekly prescription tracker assesses US prescription data and US monthly sales reported for key drugs and therapeutic categories by Symphony Health/Bloomberg.

Takeaways from 1Q; Strong start; positive earnings momentum continues

The 1Q earnings season has seen European Pharma make strong start to the year, with positive earnings momentum continuing, key drivers performing robustly and catalysts on track.

Weekly prescription tracker

Our weekly prescription tracker assesses US prescription data and US monthly sales reported for key drugs and therapeutic categories by Symphony Health/Bloomberg.

Consensus-beating Q1, guidance unchanged

Sanofi’s Q1 results were ahead of expectations, with growth largely being driven by Dupixent, along with positive contributions from Vaccines and Consumer Healthcare. Still, 2023 guidance was maintained. Overall, we re-iterate our positive stance on Sanofi, drawing comfort from Dupixent’s robust growth prospects, strong position in Vaccines, a healthy balance sheet and expectations of improvement in R&D execution, especially given the recent successes and the change of R&D head. The re-rating th

Weekly prescription tracker

Our weekly prescription tracker assesses US prescription data and US monthly sales reported for key drugs and therapeutic categories by Symphony Health/Bloomberg.

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren

BTK inhibitors: Same same, but different

Potentially transformational new class of MS treatment; $9bn base-case market opportunity BTK inhibitors could present a potentially transformative new class of treatment for the 2.8m patients living with MS. Despite the availability of treatments which control relapses, patients continue to progress leaving a large unmet medical need. With data supporting activity on relapse control and a dual mechanism of action hypothesized to also act on disability progression independent of relapse, BTK inh

Soft Q4 + weak guidance but attractively-priced at present

Q4 sales fell short of expectations. Dupixent remained the key growth driver, supported by a good performance from Consumer Healthcare and somewhat offset by a weaker showing in Vaccines. Moreover, the 2023 guidance was weak. Nonetheless, given the healthy prospects of Dupixent, the strong positioning in Vaccines and the robust balance sheet, the firm has enough leeway to look for further growth opportunities. Sanofi looks attractively priced at the current levels, especially given the dissipati

Strong Q3 + full-year guidance upgraded

Q3 exceeded expectations, driven by a strong run for Dupixent and Vaccines, and resilient Consumer Healthcare. Consequently, the 2022 guidance was revised upwards. While some recent R&D setbacks in oncology, in addition to Zantac woes, could put more pressure on the CEO, our positive stance on the stock is supported by Dupixent’s sustained growth momentum – also backed by various newer indications in the pipeline, a dominance in vaccines and a healthy balance sheet.

Sanofi – down but certainly not out

In the last one month, Sanofi has corrected significantly vis-à-vis its Big Pharma peers. While sector-specific factors have contributed to this negative sentiment, potential fall-out from the Zantac litigations and continued R&D setbacks were the main pain-points. However, there are still plenty of positives to look forward to in this promising equity story, and we believe that this more than warranted correction has opened up an attractive entry point into the French pharma giant. Overall, our

Strong Q2; full-year outlook revised upwards

In Q2, Sanofi continued its solid growth momentum driven by a strong showing from Dupixent and the Consumer Healthcare Business. Although, Vaccines’ growth came in slightly lower than the other segments, this is not a reason to worry considering the underlying strength of the business, especially the flu vaccine. Moreover, the sustained profitability improvement meant that the firm’s transformation journey remained on track. Hence, our positive outlook on the stock is maintained.

Q1 - a good start to the year

Sanofi started 2022 on a good note, with solid growth being witnessed across the divisions. In Q1, Dupixent continued its good run, and was well-complemented by a recovering Consumer Healthcare business. While the individual Vaccines performance was slightly mixed, it remains well-poised to capitalize on recovering demand post the COVID-19 disruption. Overall, the firm’s transformation journey remains on track and, hence, our positive stock recommendation is maintained.

An encouraging 2021 + a promising outlook

Sanofi’s 2021 ended on a strong note, with positive takeaways across divisions. While there were some transient challenges in Q4, it doesn’t impact the firm’s performance momentum – also reflecting in a promising 2022 outlook. Overall, the firm remains on track to deliver on its business (transformation) promises and, hence, our positive stock recommendation is reinforced.

Strong Q3 powers another guidance upgrade

Sanofi reported an excellent Q3, with all divisions supporting the strong top-line momentum. Moreover, better sales and tight control over operations aided profitability improvements and, hence, underpinned another full-year outlook upgrade. While Sanofi has been (very) late in its COVID-19 vaccine ambitions, the strong potential in most other areas remains intact and supports our positive stock recommendation.

Initial Equity Trading Comments - 15 May 2023

LIBERUM: Aptamer* - Prelims supports growth projections

Kromek - Placing raises £7m with Open Offer of up to £1m

Kromek raised £7m (with up to £1m via an Open Offer) to strengthen the balance sheet and provide the working capital for the CT programme to bridge the gap before supply agreements with recently announced Tier 1 and Tier 2 OEMs commence in earnest. As the only independent commercial scale manufacturer of the next-generation detector (CZT) for use in CT and SPECT imaging systems, Kromek is actively engaged with 9 OEMs (both Tier 1 and Tier 2), with 3 agreements having now been signed (FC estimate

LIBERUM: Aptamer* - Initiation - Build better binders

GenAI: How to Use It

You''ve been here before, right? Blockchain, the Metaverse - and now GenAI. Could this time really be different and the hype justified? The answer to this question is rooted in how GenAI can be used in the real world. In this report we thus challenge our sector teams to identify GenAI use-cases within their industries - and those companies likely to pioneer them. The result is perhaps the broadest consideration yet of how GenAI can diffuse through the economy. Efficiency is the common theme, pr

Conference Guide

Dear Client, Welcome to the 25th BNP Paribas Exane CEO Conference, marking the quarter-centenary of our yearly flagship event. Of course, our long track record doesn''t mean we''re resting on our laurels. Each year brings adaption, evolution and progress. In 2023, we''re particularly pleased to welcome nine US companies among the 118 blue chips, 100 CEOs and 900+ investors attending. This US engagement is a symbol of a truly global research house in the making. We''re growing in North America,

Hybridan Small Cap Feast - 19 May 23

19th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Oxford BioDynamics+ (OBD, House Stock, 17p) - Expanding applications

Vetting the opportunity

Monday''s trading update caused the shares to drop 13%, leaving c28% upside on the possible all-cash offer price by EQT, set at 4,070p per share. While the market seems sceptical on the deal going through (outcome expected by June 2), we believe EQT will proceed and most likely on unchanged terms. We turn opportunistic and upgrade the shares to outperform. Destocking and European slowdown behind the trading update Destocking in the USA went deeper than expected by a couple of weeks, with inven

46 stocks, 272 charts, 690 questions

Conference compendium With the summer conference season approaching, we have collated a convenient compendium of questions and performance/valuation/data screens for all the stocks within our food, household and personal care, beverages and consumer ingredients coverage universe. Stock information Within you will find 15 updated questions for management, latest company guidance, the P/E and EV/EBIT history relative to the wider sector, the P/E history relative to the relevant sub-sector, the YTD

ReNeuron Group Prelims

Preliminary FY 2023 results from ReNeuron Group plc (RENE.L) highlight its transition via restructuring from a clinical-stage drug developer to a drug delivery platform based on its exosome technologies. As such, clinical trial spend is being minimised to cover legacy obligations only and in future will be conducted instead by partners, such as Fosun Pharma. The generation of data validating its CustomEx™ exosome platform to enable partnering and licensing transactions can be completed more cost

Hybridan Small Cap Feast - 25 May 23

25th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Funding the opportunity in medical imaging

On 18 April Kromek announced a major seven-year agreement with a Tier 1 OEM to develop and incorporate its CZT-based detectors in the OEM’s advanced medical imaging scanners, and further deals have since followed. In order to fund these opportunities, on 5 May the Group announced a fund-raise of £8m (gross). It is our assumption that the Tier 1 OEM segment targeted is the CT scanner market. This was worth an estimated US$6.7bn in 2022 and, at a 5.6% CAGR, is expected to reach US$9.92bn by 2029.

NetScientific - FY 2022 results, portfolio value increases 35%

NetScientific, an investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies announces its FY 2022 results demonstrating a 35% increase in portfolio value to £41.8m across an expanding portfolio of 24 companies. NSCI reports that its portfolio has raised c. £70m. In line with its capital light investment strategy, NSCI/EMV have supported these fund-raises selectively through £3.2m of direct investments and loans, an

Avon Protection - Termination of coverage

Edison Investment Research is terminating coverage on Avon Protection (AVON), Osirium Technologies (OSI), IQE (IQE), Kopy Goldfields (KOBY) and RhoVac (ROHVAC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.